Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191986 | 1.00 | CTSS (0.52) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL191987 | 1.00 | CTSS (0.52) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL11355325 | 0.94 | CTSS (0.54) | CTSSCTSKFOLH1NAALAD2MIF | |
| Water SCHEMBL11354350 | 0.93 | CTSS (0.56) | CTSSCTSKFOLH1NAALAD2MIF | |
| Water SCHEMBL11354352 | 0.93 | CTSS (0.56) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL11352435 | 0.89 | CTSS (0.46) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL11353497 | 0.89 | CTSS (0.46) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL15962588 | 0.88 | CTSS (0.49) | CTSSCTSKMIFPPARAATM | |
| SCHEMBL8513252 | 0.88 | CTSS (0.52) | CTSSCTSKPPARAATMPPARG | |
| SCHEMBL12195416 | 0.88 | CTSS (0.52) | CTSSCTSKPPARAATMPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235017-A1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | claimed |
| WO-2009080488-A1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | claimed |
| US-20240360103-A1 | COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2024-10-31 | — | — | US | disclosed |
| EP-4119560-B1 | APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023250059-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250060-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023227734-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282862-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2023-11-29 | — | — | EP | disclosed |
| EP-4119560-A1 | APOPTOSIS-INDUCING AGENTS | Shanghai Fochon Pharmaceutical Co., Ltd. (CN) | 2023-01-18 | — | — | EP | disclosed |
| US-20220402913-A1 | APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-11091478-B2 | Apoptosis-inducing agents | FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2004063198-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-6077952-A | Cephaloporins and homologues | PFIZER INC. (US) | 2000-06-20 | — | — | US | disclosed |
| US-6020329-A | Cephaloporins and homologues, preparations and pharmaceutical compositions | PZIFER INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-6001997-A | Cephalosporins and homologues, preparations and pharmaceutical compositions | BATESON JOHN HARGREAVES (GB) | 1999-12-14 | — | — | US | disclosed |
| CN-1015714-B | PREPN. OF 7-AMINO-3-PROPENYLCEPHALOSPORANIC ACID AND ESTERS THEREOF | BRISTOL MYERS CO (US) | 1992-03-04 | — | — | CN | disclosed |
| WO-1992001696-A1 | CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1992-02-06 | — | — | WO | disclosed |
| CN-86102630-A | The method for preparing 7-amino-3-propenylcephalosporanic acid and ester class thereof | — | 1987-02-04 | — | — | CN | disclosed |
| US-3940354-A | BACTERICIDE | ROUSSEL-UCLAF (FR) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402913-A1 | APOPTOSIS-INDUCING AGENTS | BCL2, BAX, BAD | CTSS 1547/4885CTSK 1065/4885FOLH1 2947/4885 |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | CTSS 1108/4885CTSK 375/4885FOLH1 3753/4885 |
| US-20240360103-A1 | COMPLEMENT INHIBITION | C5, C9, C1QBP | CTSS 238/4885CTSK 405/4885FOLH1 1885/4885 |
| US-11091478-B2 | Apoptosis-inducing agents | BCL2, BAX, BAD | CTSS 1547/4885CTSK 1065/4885FOLH1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.